Skip Nav

Contact Us

Chondrosarcoma CS Foundation, Inc.

Thank you for your interest in our company. Complete the form below to send us an email, or simply give us a call. We're looking forward to working with you.

  • 301-352-3042

    Thank You!

    Your message has been sent.

    Oops, message not sent.

    Please make sure fields are complete.

    News

    Targeting survivin as a potential new treatment for chondrosarcoma of bone


    Targeting survivin as a potential new treatment for chondrosarcoma of bone Y de Jong, J G van Oosterwijk, A B Kruisselbrink, I H Briaire-de Bruijn, G Agrogiannis, Z Baranski, A H G Cleven, A-M Cleton-Jansen, B van de Water, E H J Danen & J V M…

    Read Article

    Bone and Soft Tissue Pathology Education


    Happy New Year! Another new set of 8 teaching cases has been uploaded to the Johns Hopkins Bone and Soft Tissue Pathology Teaching Website (https://apps.pathology.jhu.edu/bone/). Please note that previous difficulties accessing the images which…

    Read Article

    Chondrosarcoma Awareness Day: Petition to Increase Research and Clinical Trials


    Read Article

    Chordoma and Chondrosarcoma of the Skull Base Literature Review


    Chordoma and Chondrosarcoma of the Skull Base.pdf

    Read Article

    Your Support Saves Lives: Help Us Build A Chondrosarcoma Patient Registry


    Our GoFundMe is still live! The CS Foundation is committed to improving the treatment of patients living with this rare bone & soft tissue cancer. We are currently raising money for the development of a Patient Registry & Natural History…

    Read Article

    Johns Hopkins Bone Pathology Cases


    This is a website we have created geared for educational purposes in bone and soft tissue pathology. A new series of videos that have been uploaded to the site. Will be making multiple videos covering everything you could ever want to know about…

    Read Article

    Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma


    – Orphan-drug designation follows fast track designation granted to INBRX-109 in conventional chondrosarcoma – Preliminary median progression-free survival (PFS) of 7.4 months and disease control rate of 89% observed in conventional chondrosarcoma…

    Read Article

    A Genetic Model for Central Chondrosarcoma Evolution Correlates with Patient Outcome


    View ORCID ProfileWilliam Cross, Iben Lyskjær, Tom Lesluyes, Steven Hargreaves, Anna-Christina Strobl, Christopher Davies, Sara Waise, Shadi Hames, Dahmane Oukrif, Hongtao Ye, Fernanda Amary, Roberto Tirabosco, Toby Baker, David Barnes,…

    Read Article

    Contact Information


    If you would like to learn more about CS Foundation or if you would like to learn more about the resources we provide to patients, families, caregivers, and physicians, please contact us by phone or send us a message.

    **A Registered 501c3 Non-Profit Charity Organization. All donations are tax-deductible.**

    Send a Message